Suppr超能文献

Exciting science from the 16th International Conference on Thalassemia and Hemoglobinopathies.

作者信息

Farmakis Dimitrios, Angastiniotis Michael, Eleftheriou Androulla

机构信息

Thalassaemia International Federation Nicosia Cyprus.

National and Kapodistrian University of Athens Medical School Athens Greece.

出版信息

Hemasphere. 2024 Jul 19;8(7):e114. doi: 10.1002/hem3.114. eCollection 2024 Jul.

Abstract
摘要

相似文献

1
Exciting science from the 16th International Conference on Thalassemia and Hemoglobinopathies.
Hemasphere. 2024 Jul 19;8(7):e114. doi: 10.1002/hem3.114. eCollection 2024 Jul.
3
The epidemiologic transition of thalassemia and associated hemoglobinopathies in southern Taiwan.
Ann Hematol. 2017 Feb;96(2):183-188. doi: 10.1007/s00277-016-2868-7. Epub 2016 Nov 28.
4
Foreword: Advances in Hemoglobinopathies.
Acta Biomed. 2021 Sep 2;92(4):e2021410. doi: 10.23750/abm.v92i4.11927.
5
The interactions of alpha-thalassemia with hemoglobinopathies.
Hematol Oncol Clin North Am. 1991 Jun;5(3):453-73.
6
The Prevention of Thalassemia Revisited: A Historical and Ethical Perspective by the Thalassemia International Federation.
Hemoglobin. 2021 Jan;45(1):5-12. doi: 10.1080/03630269.2021.1872612. Epub 2021 Jan 18.
7
Thalassemias and hemoglobinopathies in Turkey.
Hemoglobin. 2014;38(5):305-7. doi: 10.3109/03630269.2014.938163. Epub 2014 Jul 17.
8
Diabetes in Patients with ß-thalassemia or other Hemoglobinopathies - Analysis from the DPV Database.
Klin Padiatr. 2016 Nov;228(6-07):307-312. doi: 10.1055/s-0042-111691. Epub 2016 Nov 15.
9
Carrier screening for thalassemia and hemoglobinopathies in Canada.
J Obstet Gynaecol Can. 2008 Oct;30(10):950-959. doi: 10.1016/S1701-2163(16)32975-9.

本文引用的文献

2
One-year safety and efficacy of mitapivat in sickle cell disease: follow-up results of a phase 2, open-label study.
Blood Adv. 2023 Dec 26;7(24):7539-7550. doi: 10.1182/bloodadvances.2023011477.
3
Recent Advances in Sickle-Cell Disease Therapies: A Review of Voxelotor, Crizanlizumab, and L-glutamine.
Pharmacy (Basel). 2022 Sep 26;10(5):123. doi: 10.3390/pharmacy10050123.
6
Betibeglogene Autotemcel Gene Therapy for Non-β/β Genotype β-Thalassemia.
N Engl J Med. 2022 Feb 3;386(5):415-427. doi: 10.1056/NEJMoa2113206. Epub 2021 Dec 11.
7
CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia.
N Engl J Med. 2021 Jan 21;384(3):252-260. doi: 10.1056/NEJMoa2031054. Epub 2020 Dec 5.
8
A Phase 3 Trial of Luspatercept in Patients with Transfusion-Dependent β-Thalassemia.
N Engl J Med. 2020 Mar 26;382(13):1219-1231. doi: 10.1056/NEJMoa1910182.
10
Healthcare costs and outcomes of managing β-thalassemia major over 50 years in the United Kingdom.
Transfusion. 2016 May;56(5):1038-45. doi: 10.1111/trf.13513. Epub 2016 Apr 4.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验